{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:36:27Z","timestamp":1793223387991,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["CBM.THROX.03.10.RD.006"],"award-info":[{"award-number":["CBM.THROX.03.10.RD.006"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The continuous emergence of infectious pathogens along with antimicrobial resistance creates a need for an alternative approach to treat infectious diseases. Targeting host factor(s) which are critically involved in immune signaling pathways for modulation of host immunity offers to treat a broad range of infectious diseases. Upon pathogen-associated ligands binding to the Toll-like\/ IL-1R family, and other cellular receptors, followed by recruitment of intracellular signaling adaptor proteins, primarily MyD88, trigger the innate immune responses. But activation of host innate immunity strongly depends on the correct function of MyD88 which is tightly regulated. Dysregulation of MyD88 may cause an imbalance that culminates to a wide range of inflammation-associated syndromes and diseases. Furthermore, recent reports also describe that MyD88 upregulation with many viral infections is linked to decreased antiviral type I IFN response, and MyD88-deficient mice showed an increase in survivability. These reports suggest that MyD88 is also negatively involved via MyD88-independent pathways of immune signaling for antiviral type I IFN response. Because of its expanding role in controlling host immune signaling pathways, MyD88 has been recognized as a potential drug target in a broader drug discovery paradigm. Targeting BB-loop of MyD88, small molecule inhibitors were designed by structure-based approach which by blocking TIR\u2013TIR domain homo-dimerization have shown promising therapeutic efficacy in attenuating MyD88-mediated inflammatory impact, and increased antiviral type I IFN response in experimental mouse model of diseases. In this review, we highlight the reports on MyD88-linked immune response and MyD88-targeted therapeutic approach with underlying mechanisms for controlling inflammation and antiviral type I IFN response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\u2022 Host innate immunity is activated upon PAMPs binding to PRRs followed by immune signaling through TIR domain\u2013containing adaptor proteins mainly MyD88.<\/jats:p>\n                    <jats:p>\u2022 Structure-based approach led to develop small-molecule inhibitors which block TIR domain homodimerization of MyD88 and showed therapeutic efficacy in limiting severe inflammation-associated impact in mice.<\/jats:p>\n                    <jats:p>\u2022 Therapeutic intervention of MyD88 also showed an increase in antiviral effect with strong type I IFN signaling linked to increased phosphorylation of IRFs via MyD88\u2013independent pathway.<\/jats:p>\n                    <jats:p>\u2022 MyD88 inhibitors might be potentially useful as a small-molecule therapeutics for modulation of host immunity against inflammatory diseases and antiviral therapy.<\/jats:p>\n                    <jats:p>\u2022 However, prior clinical use of more in-depth efforts should be focused for suitability of the approach in deploying to complex diseases including COPD and COVID-19 in limiting inflammation-associated syndrome to infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12026-021-09188-2","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T16:04:06Z","timestamp":1617897846000},"page":"117-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity"],"prefix":"10.1007","volume":"69","author":[{"given":"Kamal U.","family":"Saikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"issue":"3","key":"9188_CR1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.immuni.2010.03.012","volume":"32","author":"AL Blasius","year":"2010","unstructured":"Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305\u201315.","journal-title":"Immunity."},{"issue":"5","key":"9188_CR2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","volume":"34","author":"YM Loo","year":"2011","unstructured":"Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680\u201392.","journal-title":"Immunity"},{"key":"9188_CR3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-immunol-031210-101352","volume":"30","author":"D Sancho","year":"2012","unstructured":"Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol. 2012;30:491\u2013529.","journal-title":"Annu Rev Immunol."},{"issue":"6","key":"9188_CR4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805\u201320.","journal-title":"Cell"},{"issue":"9","key":"9188_CR5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nri1900","volume":"6","author":"K Honda","year":"2006","unstructured":"Honda K, Taniguchi T. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6(9):644\u201358.","journal-title":"Nat Rev Immunol"},{"key":"9188_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","volume":"21","author":"K Takeda","year":"2003","unstructured":"Takeda K, Kaisho T. Akira S Toll-like receptors. Annu Rev Immunol. 2003;21:335\u201376.","journal-title":"Annu Rev. Immunol."},{"key":"9188_CR7","first-page":"1095","volume":"5","author":"KA Lord","year":"1990","unstructured":"Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene. 1990;5:1095\u20137.","journal-title":"Oncogene"},{"key":"9188_CR8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.278.5343.1612","volume":"278","author":"M Muzio","year":"1997","unstructured":"Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science. 1997;278:1612\u20135.","journal-title":"Science"},{"key":"9188_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1074-7613(00)80402-1","volume":"7","author":"H Wesche","year":"1997","unstructured":"Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997;7:837\u201347.","journal-title":"Immunity"},{"issue":"9","key":"9188_CR10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nri1900","volume":"6","author":"K Honda","year":"2006","unstructured":"Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6(9):644\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"9188_CR11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/sj.icb.7100095","volume":"85","author":"TM Watters","year":"2007","unstructured":"Watters TM, Kenny EF, O\u2019Neill LA. Structure, function and regulation of the Toll\/IL-1 receptor adaptor proteins. Immunol Cell Biol. 2007;85(6):411\u20139.","journal-title":"Immunol Cell Biol."},{"issue":"4","key":"9188_CR12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0022034510381264","volume":"90","author":"J Brown","year":"2011","unstructured":"Brown J, Wang H, Hajishengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res. 2011;90(4):417\u201327.","journal-title":"J Dent Res"},{"issue":"6851","key":"9188_CR13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/35092578","volume":"413","author":"KA Fitzgerald","year":"2001","unstructured":"Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. 2001;413(6851):78\u201383.","journal-title":"Nature"},{"issue":"6913","key":"9188_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature01180","volume":"420","author":"T Horng","year":"2002","unstructured":"Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 2002;420(6913):329\u201333.","journal-title":"Nature"},{"issue":"5633","key":"9188_CR15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","volume":"301","author":"M Yamamoto","year":"2003","unstructured":"Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301(5633):640\u20133.","journal-title":"Science"},{"issue":"11","key":"9188_CR16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ni986","volume":"4","author":"M. Sato Yamamoto","year":"2003","unstructured":"Yamamoto M. Sato, S, Hemmi H, , et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol. 2003;4(11):1144\u201350.","journal-title":"Nat Immunol."},{"issue":"5","key":"9188_CR17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2079","volume":"7","author":"LA O'Neill","year":"2007","unstructured":"O\u2019Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7(5):353\u201364.","journal-title":"Nat Rev Immunol."},{"key":"9188_CR18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0968-0004(02)02145-X","volume":"27","author":"S Janassens","year":"2002","unstructured":"Janassens S, Beyart R. A universal role of Myd88 in TLR\/IL-1R-mediated signaling. Trends Biochem Sci. 2002;27:474\u201382.","journal-title":"Trends Biochem Sci"},{"key":"9188_CR19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0022034510381264","volume":"90","author":"J Brown","year":"2011","unstructured":"Brown J, Wang H, Hajishshengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases and cross-talk. J Dent Res. 2011;90:417\u201327.","journal-title":"J Dent Res"},{"key":"9188_CR20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783\u2013801.","journal-title":"Cell"},{"key":"9188_CR21","first-page":"re3","volume":"171","author":"A Dunne","year":"2003","unstructured":"Dunne A, O\u2019Neill LA. The interleukin-1 receptor\/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003;171:re3.","journal-title":"Sci STKE"},{"key":"9188_CR22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1097-2765(00)80136-7","volume":"2","author":"R Medzhitov","year":"1998","unstructured":"Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr. MyD88 is an adaptor protein in the hToll\/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253\u20138.","journal-title":"Mol. Cell"},{"key":"9188_CR23","first-page":"2467","volume":"13","author":"G Hardiman","year":"1996","unstructured":"Hardiman G, Rock FL, Balasubramanian S, Kastelein RA, Bazan F. Molecular characterization and modular analysis of human MyD88. Oncogene. 1996;13:2467\u201375.","journal-title":"Oncogene"},{"key":"9188_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1084\/jem.20021790","volume":"197","author":"K Burns","year":"2003","unstructured":"Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor\/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med. 2003;197:263\u20138.","journal-title":"J. Exp. Med."},{"key":"9188_CR25","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.4049\/jimmunol.1100515","volume":"187","author":"M Avbelj","year":"2011","unstructured":"Avbelj M, Horvat S, Roman Jerala R. The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs. J Immunol. 2011;187:2394\u2013404.","journal-title":"J Immunol"},{"key":"9188_CR26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1097-2765(00)80136-7","volume":"2","author":"R Medzhitov","year":"1998","unstructured":"Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr. MyD88 is an adaptor protein in the hToll\/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253\u20138.","journal-title":"Mol Cell"},{"key":"9188_CR27","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1074\/jbc.273.20.12203","volume":"273","author":"K Burns","year":"1998","unstructured":"Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, Di Marco F, French L, Tschopp J. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem. 1998;273:12203\u20139.","journal-title":"J. Biol. Chem."},{"key":"9188_CR28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature09121","volume":"465","author":"SC Lin","year":"2010","unstructured":"Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4- IRAK2 complex in TLR\/IL-1R signalling. Nature. 2010;465:885\u201390.","journal-title":"Nature"},{"key":"9188_CR29","doi-asserted-by":"crossref","unstructured":"Xu Y, Tao X, Shen B, Horng, T, Medzhitov R, Manley JL, and Tong, L. Structural Basis for Signal Transduction by the Toll-interleukin-I receptor domains. Nature. 2000;408:111\u2013115.","DOI":"10.1038\/35040600"},{"key":"9188_CR30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1074-7613(00)80596-8","volume":"9","author":"O Adachi","year":"1998","unstructured":"Adachi O, Kawai T, Takeda KK, Matsumuto M, Tsutsui H, Sakagami M, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998;9:143\u201350.","journal-title":"Immunity"},{"key":"9188_CR31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ni1308","volume":"7","author":"D Sun","year":"2006","unstructured":"Sun D, Ding A. MyD88-mediated stabilization of interferon-\u03b3-induced cytokine and chemokine mRNA. Nat Immunol. 2006;7:375\u201381.","journal-title":"Nat. Immunol."},{"key":"9188_CR32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ni.2015","volume":"12","author":"X Liu","year":"2011","unstructured":"Liu X, Zhan Z, Li D, Xu L, Ma F, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011;12:416\u201324.","journal-title":"Nat Immunol"},{"key":"9188_CR33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ni.2023","volume":"12","author":"GS Hassan","year":"2011","unstructured":"Hassan GS, Mourad W. An unexpected role for MHC class II. Nat Immunol. 2011;12:375\u20136.","journal-title":"Nat Immunol"},{"key":"9188_CR34","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.172.5.1513","volume":"172","author":"W Mourad","year":"1990","unstructured":"Mourad W, Geha RS. Chatila T Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. J Exp Med. 1990;172:1513\u20136.","journal-title":"J Exp Med"},{"key":"9188_CR35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4049\/jimmunol.149.1.65","volume":"149","author":"F Spertini","year":"1992","unstructured":"Spertini F, Chatila T, Geha RS. Signals delivered via MHC class II molecules synergize with signals delivered via TCR\/CD3 to cause proliferation and cytokine gene expression in T cells. 1992. J Immunol. 1992;149:65\u201370.","journal-title":"J Immunol"},{"key":"9188_CR36","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/eji.1830231139","volume":"23","author":"S Hauschildt","year":"1993","unstructured":"Hauschildt S, Bessler WG. Scheipers P (1993) Engagement of major histocompatibility complex class II molecules leads to nitrite production in bone marrow-derived macrophages. Eur J Immunol. 1993;23:2988\u201392.","journal-title":"Eur J Immunol"},{"key":"9188_CR37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0966-842X(00)89011-3","volume":"3","author":"RG Ulrich","year":"1995","unstructured":"Ulrich RG, Bavari S. Olson MA (1995) Bacterial superantigens in human disease: structure, function and diversity. Trends Microbiol. 1995;3:463\u20138.","journal-title":"Trends Microbiol"},{"key":"9188_CR38","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1128\/IAI.61.12.5333-5338.1993","volume":"61","author":"BG Stiles","year":"1993","unstructured":"Stiles BG, Bavari S, Krakauer T, Ulrich RG. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infect Immun. 1993;61:5333\u20138.","journal-title":"Infect Immun"},{"key":"9188_CR39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1753425910374092","volume":"17","author":"TL Kissner","year":"2011","unstructured":"Kissner TL, Ruthel G, Cisney ED, Ulrich RG, Fernandez S, Saikh KU. MyD88-dependent pro-inflammatory cytokine response contributes to lethal toxicity of staphylococcal enterotoxin B in mice. Innate Immun. 2011;17:451\u201362.","journal-title":"Innate Immun"},{"key":"9188_CR40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2567.2010.03249.x","volume":"130","author":"TL Kissner","year":"2010","unstructured":"Kissner TL, Cisney ED, Ulrich RG, Fernandez S, Saikh KU. Staphylococcal enterotoxin A induction of pro-inflammatory cytokines and lethality in mice is primarily dependent on MyD88. Immunol. 2010;130:516\u201326.","journal-title":"Immunol"},{"issue":"1","key":"9188_CR41","doi-asserted-by":"crossref","first-page":"e15985","DOI":"10.1371\/journal.pone.0015985","volume":"6","author":"TL Kissner","year":"2011","unstructured":"Kissner TL, Ruthel G, Cisney ED, Ulrich RG, Fernandez S, Saikh KU. Activation of MyD88 signaling upon Staphylococcal enterotoxin binding to MHC class II molecules. PLoS ONE. 2011;6(1):e15985.","journal-title":"PLoS ONE"},{"key":"9188_CR42","first-page":"31385","volume":"286","author":"TL Kissner","year":"2011","unstructured":"Kissner TL, Moisan L, Mann E, Ulrich RG, Ping S, Waugh DS, Rebek M, Rebek J, Saikh KU. A small molecule that mimics the BB-loop in Toll\/IL-1 receptor domain of MyD88 attenuate Staphylococcal enterotoxin induced cytokine production and toxic shock in mice. J BiolChem. 2011;286:31385\u201396.","journal-title":"J BiolChem"},{"key":"9188_CR43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/35040600","volume":"408","author":"Y Xu","year":"2000","unstructured":"Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L. Structural basis for signal transduction by the Toll\/interleukin-1 receptor domains. Nature. 2000;408:111\u20135.","journal-title":"Nature."},{"key":"9188_CR44","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1073\/pnas.0932746100","volume":"100","author":"T Bartfai","year":"2003","unstructured":"Bartfai T, Behrens MM, Gaidarova S, Pemberton J, Shivanyuk A, Rebek J Jr. A low molecular weight mimic of the TIR-domain inhibits interleukin 1 receptor-mediated responses. Proc Natl Acad Sci USA. 2003;100:7971\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"9188_CR45","doi-asserted-by":"crossref","first-page":"e40773","DOI":"10.1371\/journal.pone.0040773","volume":"7","author":"TL Kissner","year":"2012","unstructured":"Kissner TL, Ruthel G, Alam S, Mann E, Ajami DE, Rebek M, Larkin ES, Fernandez S, Ulrich RG, Ping S, Waugh DS, J Rebek Jr, Saikh KU. Therapeutic inhibition of pro-inflammatory signaling and toxicity to staphylococcal enterotoxin B by a synthetic dimeric BB-loop mimetic of MyD88. PLoS ONE. 2012;7(7):e40773.","journal-title":"PLoS ONE"},{"key":"9188_CR46","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1073\/pnas.0510802103","volume":"103","author":"CN Davis","year":"2006","unstructured":"Davis CN, Mann E, Behrens MM, Gaidarova S, Rebek M, Rebek J Jr, Bartfai T. MyD88- dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll\/IL-1 receptor domain\/BB-loop mimetics. Proc Natl Acad Sci U S A. 2006;103:2953\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9188_CR47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cbdd.12477","volume":"86","author":"S Alam","year":"2015","unstructured":"Alam S, Javor S, Degardin M, Ajami D, Rebek M, Kissner TL, Waag DM, Rebek J Jr, Saikh KU. Structure-based design and synthesis of a small molecule that exhibits anti-inflammatory activity by inhibition of MyD88- mediated signaling to bacterial toxin exposure. Chem Biol Drug Design. 2015;86:200\u20139.","journal-title":"Chem Biol Drug Design"},{"key":"9188_CR48","unstructured":"Saikh, KU., Rebek, JM, Glass PJ. Small molecule inhibitor of MyD88 for therapeutic treatment against alphavirus and staphylococcal enterotoxin infections and toxin exposure. Patent# US 9,833,437 B2."},{"issue":"6","key":"9188_CR49","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/cbdd.13039","volume":"90","author":"DA Ryan","year":"2017","unstructured":"Ryan DA, Degardin M, Alam S, Kissner TL, Hale M, Cameron MD, Rebek M, Ajami D, Saikh KU, Rebek J Jr. Rational design of peptide derivatives for inhibition of MyD88-mediated TLR signaling in human PBMCs and epithelial cells exposed to F. tularensis. ChemBiol Drug Des. 2017;90(6):1190\u2013205.","journal-title":"ChemBiol Drug Des"},{"key":"9188_CR50","doi-asserted-by":"publisher","first-page":"14246","DOI":"10.1038\/srep14246","volume":"5","author":"MA Olson","year":"2015","unstructured":"Olson MA, Lee MS, Kissner TL, Alam S, Waugh DS, Saikh KU. Discovery of small molecule inhibitors of MyD88-dependent signaling pathways using a computational screen Sci. Rep. 2015;5:14246. https:\/\/doi.org\/10.1038\/srep14246.","journal-title":"Rep"},{"key":"9188_CR51","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2018.1464139","volume":"25","author":"FD Padova","year":"2018","unstructured":"Padova FD, Quesniaux VFJ, Ryffel B. MyD88 as a therapeutic target for inflammatory diseases. Expert OpinTher Targets. 2018;25:401\u20138.","journal-title":"Expert OpinTher Targets"},{"key":"9188_CR52","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1189\/jlb.1206746","volume":"82","author":"M Loiarro","year":"2007","unstructured":"Loiarro M, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007;82:801\u201310.","journal-title":"J Leukoc Biol"},{"key":"9188_CR53","first-page":"15809","volume":"280","author":"M Loiarro","year":"2005","unstructured":"Loiarro M, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependentactivation of NF-{kappa}. B J BiolChem. 2005;280:15809\u201314.","journal-title":"B J BiolChem"},{"issue":"4","key":"9188_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/FJC.0b013e3181d3da24","volume":"55","author":"BW Van Tassell","year":"2010","unstructured":"Van Tassell BW, Seropian IM, Toldo S, Salloum FN, Smithson L, Varma A, Hoke NN, Gelwix C, Chau V, Abbate AJ. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. Cardiovasc Pharmacol. 2010 Apr;55(4):385\u201390. https:\/\/doi.org\/10.1097\/FJC.0b013e3181d3da24 (PMID: 20125030).","journal-title":"Cardiovasc Pharmacol"},{"key":"9188_CR55","doi-asserted-by":"publisher","unstructured":"Lin Xie\u00a0,\u00a0Feng-Chao Jiang\u00a0,\u00a0Li-Min Zhang\u00a0,\u00a0Wen-Tao He\u00a0,\u00a0Jian-Hua Liu\u00a0,\u00a0Ming-Qiang Li\u00a0,\u00a0Xue Zhang\u00a0,\u00a0Shuai Xing,\u00a0Hui Guo\u00a0,\u00a0Ping Zhou. .Targeting of My88 homodimerization by novel synthetic inhibitor TJ-M2010\u20135 in preventing colitis-associated colorectal cancer. J Natl Cancer Inst. 2015 Dec 28;108 (4):djv364. doi: https:\/\/doi.org\/10.1093\/jnci\/djv364.\u00a0Print 2016 Apr.","DOI":"10.1093\/jnci\/djv364"},{"key":"9188_CR56","doi-asserted-by":"crossref","unstructured":"Greg A. Snyder, Lindsey J. Brown, Savannah Taylor, Ciara E. Faupel, Matthew Sherman, Justin J. Montague, Kamal Saikh and Yajing Wang. Targeting of diffuse large B-cell lymphomas using MyD88 small molecule inhibitors. J. Immunol. May 1, 2018, 2019 (1 Supplement) 169.17","DOI":"10.4049\/jimmunol.200.Supp.169.17"},{"key":"9188_CR57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.chom.2016.01.006","volume":"19","author":"BR TenOver","year":"2016","unstructured":"TenOver BR. The Evolution of antiviral defense systems. Cell Host Microbe. 2016;19:142\u20139.","journal-title":"Cell Host Microbe"},{"key":"9188_CR58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","volume":"20","author":"CA Janeway Jr","year":"2002","unstructured":"Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev immunol. 2002;20:197\u2013216.","journal-title":"Annu Rev immunol"},{"key":"9188_CR59","doi-asserted-by":"publisher","unstructured":"Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol.2014; 32:461\u00b188. https:\/\/doi.org\/https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120156 PMID: 24655297)","DOI":"10.1146\/annurev-immunol-032713-120156"},{"key":"9188_CR60","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1462-5822.2006.00716.x","volume":"8","author":"A Takeda","year":"2006","unstructured":"Takeda A, Yanai H. Interferon signaling network in innate defense. Cell Microbiol. 2006;8:907\u201322.","journal-title":"Cell Microbiol"},{"key":"9188_CR61","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/107999002760274845","volume":"22","author":"MM Brierle","year":"2002","unstructured":"Brierle MM, Fish EN. IFN- alpha beta receptor interactions to biologic outcomes; understanding the circuitry. J Interferon Cytokine Res. 2002;22:835\u201345.","journal-title":"J Interferon Cytokine Res"},{"key":"9188_CR62","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50:907\u201323.","journal-title":"Immunity"},{"key":"9188_CR63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-immunol-042718-041356","volume":"37","author":"S Hur","year":"2019","unstructured":"Hur S. Double stranded RNA sensors and modulators of innate immunity. Annu Rev Immunol. 2019;37:349\u201375.","journal-title":"Annu Rev Immunol"},{"key":"9188_CR64","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.it.2012.01.004","volume":"33","author":"BX Wang","year":"2012","unstructured":"Wang BX, Fish EN. The yin and yang of viruses and Interferons. Trends Immunol. 2012;33:190\u20137.","journal-title":"Trends Immunol"},{"issue":"10","key":"9188_CR65","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1517\/14712598.2010.521495","volume":"10","author":"R Toporovski","year":"2010","unstructured":"Toporovski R, Morrow MP, Weiner DB. Interferons as potential adjuvants in prophylactic vaccines. Expert Opin Biol Ther. 2010;10(10):1489\u2013500. https:\/\/doi.org\/10.1517\/14712598.2010.521495 (PMID: 20836750).","journal-title":"Expert Opin Biol Ther"},{"key":"9188_CR66","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1016\/j.antiviral.2020.104791","volume":"178","author":"E Sallard","year":"2020","unstructured":"Sallard E, Lescure F-X, Yazdanapanah Y, Mentre F, Peiffer-Smadja N. Antiviral Res. 2020;178:10479.","journal-title":"Antiviral Res"},{"issue":"19","key":"9188_CR67","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1146\/annurev.immunol.19.1.623","volume":"2001","author":"T Taniguchi","year":"2001","unstructured":"Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;2001(19):623\u201355.","journal-title":"Annu Rev Immunol"},{"key":"9188_CR68","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/MCB.18.5.2986","volume":"18","author":"R Lin","year":"1998","unstructured":"Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome mediated degradation. Mol Cell Biol. 1998;18:2986\u201396.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"9188_CR69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1359-6101(97)00019-1","volume":"1997","author":"H Nguyen","year":"1997","unstructured":"Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 1997;1997(8):293\u2013312.","journal-title":"Cytokine Growth Factor Rev"},{"key":"9188_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(99)00262-0","volume":"237","author":"Y Mamane","year":"1999","unstructured":"Mamane Y, Heylbroeck C, G\u00e9nin P, Algart\u00e9 M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R, Hiscott J. Interferon regulatory factors: the next generation. Gene. 1999;237:1\u201314.","journal-title":"Gene"},{"key":"9188_CR71","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nature03464","volume":"434","author":"K Honda","year":"2005","unstructured":"Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-1 interferon-dependent immune responses. Nature. 2005;434:772\u20137.","journal-title":"Nature"},{"key":"9188_CR72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ni921","volume":"4","author":"KA Fitzgerald","year":"2003","unstructured":"Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. IKK epsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4:491\u20136.","journal-title":"Nat. Immunol"},{"issue":"40","key":"9188_CR73","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1002\/eji.201040547","volume":"2010","author":"J Siednienko","year":"2010","unstructured":"Siednienko J, Halle A, Nagpal K, Golenbock DT, Miggin SM. TLR3-mediated IFN-\u03b2 gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like. Eur J Immunol. 2010;2010(40):3150\u201360.","journal-title":"Eur J Immunol"},{"key":"9188_CR74","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.4049\/jimmunol.1003093","volume":"186","author":"J Siednienko","year":"2011","unstructured":"Siednienko J, Gajanayake T, Fitzgerald KA, Moynagh P, Miggin SM. Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-\u03b2 and RANTES production. J Immunol. 2011;186:2514\u201322.","journal-title":"J Immunol"},{"issue":"90","key":"9188_CR75","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1128\/JVI.00262-16","volume":"2016","author":"R Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s R, Ben Haij N, Leghmari K, Serrero M, BenMohamed L, Bahraoui E. HIV-1 Tat protein activates both the MyD88 and TRIF pathways to induce tumor necrosis factor alpha and interleukin-10 in human monocytes. J Virol. 2016;2016(90):5886\u201398.","journal-title":"J Virol"},{"key":"9188_CR76","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/HYPERTENSIONAHA.115.06011","volume":"66","author":"MV Singh","year":"2015","unstructured":"Singh MV, Cicha MZ, Meyerholz DK, Chapleau MW, Abboud FM. Dual activation of TRIF and MyD88 adaptor proteins by angiotensin II evokes opposing effects on pressure, cardiac hypertrophy, and inflammatory gene expression. Hypertension. 2015;66:647\u201356.","journal-title":"Hypertension"},{"key":"9188_CR77","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.0901140","volume":"183","author":"EF Kenny","year":"2009","unstructured":"Kenny EF, Talbot S, Gong M, Golenbock DT, Bryant CE, O\u2019Neill LA. MyD88 adaptor like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol. 2009;183:3642\u201351.","journal-title":"J Immunol"},{"key":"9188_CR78","first-page":"3988","volume":"278","author":"AC Johnson","year":"2003","unstructured":"Johnson AC, Li X, Pearlman E. MyD88 functions as a negative regulator of TLR3\/TRIFinduced corneal inflammation by inhibiting activation of c-Jun N-terminal kinase. J Biol Chem. 2003;278:3988\u201339960.","journal-title":"J Biol Chem"},{"key":"9188_CR79","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1084\/jem.20081210","volume":"205","author":"T Saito","year":"2008","unstructured":"Saito T, Gale M Jr. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp Med. 2008;205:1523\u20137.","journal-title":"Exp. Med"},{"key":"9188_CR80","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/CIRCULATIONAHA.105.536433","volume":"112","author":"K Fuse","year":"2005","unstructured":"Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, Chen M, Yeh WC, Akira S, Liu PP. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3 induced myocarditis and influences type I interferon production. Circulation. 2005;112:2276\u201385.","journal-title":"Circulation"},{"issue":"90","key":"9188_CR81","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1099\/vir.0.010280-0","volume":"2009","author":"A Sharma","year":"2009","unstructured":"Sharma A, Maheshwari R. Oligonucleotide array analysis of Toll-like receptors and associated signaling genes in Venezuelan equine encephalitis virus-infected mouse brain. J Gen Virol. 2009;2009(90):1836\u201347.","journal-title":"J Gen Virol"},{"key":"9188_CR82","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.celrep.2016.01.049","volume":"14","author":"MR Edwards","year":"2016","unstructured":"Edwards MR, Liu G, Mire CE, Sureshchandra S, Luthra P, Yen B, Shabman RS, Leung DW, Messaoudi I, Geisbert TW, Amarasinghe GK, Basler CF. Differential regulation of interferon responses by ebola and Marburg virus VP35 proteins. Cell Rep. 2016;14:1632\u201340.","journal-title":"Cell Rep"},{"key":"9188_CR83","doi-asserted-by":"publisher","first-page":"104854","DOI":"10.1016\/j.antiviral.2020.104854","volume":"181","author":"KU Saikh","year":"2020","unstructured":"Saikh KU, Piper A, Bakken RR, Glass PJ. A small molecule inhibitor of MyD88 exhibits broad spectrum antiviral activity by up regulation of Type I Interferon. Antiviral Research. 2020 Sep;181:104854. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104854.","journal-title":"Antiviral Research"},{"key":"9188_CR84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jir.2013.0035","volume":"34","author":"N Ayithan","year":"2014","unstructured":"Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Dye JM, Bavari S, Bray M, Ozato K. Ebola virus-like particles stimulate type I interferons and pro-inflammatory cytokine expression through the toll-like receptors and interferon signaling pathways. J Interferon Cytokine Res. 2014;34:79\u201389.","journal-title":"J Interferon Cytokine Res"},{"key":"9188_CR85","doi-asserted-by":"crossref","first-page":"e1008737","DOI":"10.1371\/journal.ppat.1008737","volume":"16","author":"MS Ribero","year":"2020","unstructured":"Ribero MS, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and type I interferon response. Plos Pathogens. 2020;16:e1008737.","journal-title":"Plos Pathogens"},{"key":"9188_CR86","doi-asserted-by":"crossref","unstructured":"Whitmore A, Agnihothram S, et al., (2015) Toll-like receptor signaling via TRIF contributes to a protective innate immune response to sever acute respiratory syndrome coronavirus infection. mBio. 6: e00638-15.","DOI":"10.1128\/mBio.00638-15"},{"key":"9188_CR87","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","volume":"20","author":"D Acharya","year":"2020","unstructured":"Acharya D, Liu GO, Gack MU. Dysregulation of type I interferon responses in Covid-19. Nat Immunol. 2020;20:397\u20138.","journal-title":"Nat Immunol"},{"key":"9188_CR88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, Jean K, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:136\u201345.","journal-title":"Cell"},{"key":"9188_CR89","doi-asserted-by":"crossref","unstructured":"Iampietro M, Aurine N, Dhondt KP, Dumont C, Pelissier R, Spanier J, Valive A, Raoul H, kalinke U, Horvat B. Control of nipah virus infection in mice by the host adaptors mitrochondrial antiviral signaling protein (MAVS) and myeloid differentiation primary response 88 (MyD88). J. Infect. Dis. 2019.Suppl. S1\u20136.","DOI":"10.1093\/infdis\/jiz602"},{"key":"9188_CR90","doi-asserted-by":"crossref","first-page":"e112918","DOI":"10.1371\/journal.pone.0112918","volume":"9","author":"ZX Zhou","year":"2014","unstructured":"Zhou ZX, Zhang BC, Sun L. Poly (I:C) induces antiviral immune responses in Japanese flounder (Paralichthysolivaceus) that require TLR3 and MDA5 and is negatively regulated by MyD88. PLoS One. 2014;9:e112918.","journal-title":"PLoS One"},{"issue":"36","key":"9188_CR91","first-page":"49","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses Nat. Rev Immunol. 2014;14(36):49.","journal-title":"Rev. Immunol."},{"key":"9188_CR92","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"Bo Diao","year":"2020","unstructured":"Diao Bo, Wang Chenhui, Tan Yingjun, Chen Xiewan, Liu Ying, Ning Lifen, Che Li, Li Min, Liu Yueping, Wang Gang, Yuan Zilin, Feng Zeqing, Zhang Yi, Yuzhang Wu, Chen Yongwen. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827. https:\/\/doi.org\/10.3389\/fimmu.2020.00827.","journal-title":"Front. Immunol"},{"key":"9188_CR93","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533\u20135.","journal-title":"Cell Mol Immunol"},{"key":"9188_CR94","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","volume":"71","author":"C Qin","year":"2020","unstructured":"Qin C, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa248.","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"9188_CR95","doi-asserted-by":"crossref","first-page":"e49049","DOI":"10.1371\/journal.pone.0049049","volume":"7","author":"L Martinez-Gil","year":"2012","unstructured":"Martinez-Gil L, Ayllon J, Ortigoza MB, Garcia-satre A, Shaw ML, Palese P. Identification of small molecules with type I interferon inducing properties by High-throughput Screening. Plos one. 2012;7(11):e49049.","journal-title":"Plos one"},{"key":"9188_CR96","doi-asserted-by":"publisher","first-page":"14246","DOI":"10.1038\/srep14246","volume":"5","author":"MA Olson","year":"2015","unstructured":"Olson MA, Lee MS, Kissner TL, Alam S, Waugh DS, Saikh KU. Discovery of small molecule inhibitors of MyD88-dependent signaling pathways using a computational screen. Sci Rep. 2015;5:14246. https:\/\/doi.org\/10.1038\/srep14246.","journal-title":"Sci Rep"},{"key":"9188_CR97","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/s41598-018-20388-z","volume":"8","author":"CJ Suckling","year":"2018","unstructured":"Suckling CJ, Alam S, Olson MA, Saikh KU, Harnett MM, Harnett W. Small molecule analogues of theparasitic worm product ES-62interact with the TIR domain domain of MyD88 to inhibit pro-inflammatory signaling. Scientific Reports. 2018;8:2123. https:\/\/doi.org\/10.1038\/s41598-018-20388-z.","journal-title":"Scientific Reports."},{"key":"9188_CR98","first-page":"35","volume":"17","author":"SHE Kaufmann","year":"2018","unstructured":"Kaufmann SHE, Dorhai A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev. 2018;17:35\u201355.","journal-title":"Nat Rev"},{"issue":"5","key":"9188_CR99","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bjid.2020.07.011","volume":"24","author":"CP Sousa","year":"2020","unstructured":"Sousa CP, Brites C. Immune response in SARS-CoV-2 infection: the role of interferons type I and type III. Braz J Infect Dis. 2020;24(5):428\u201333.","journal-title":"Braz J Infect Dis"},{"key":"9188_CR100","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadji","year":"2020","unstructured":"Hadjadji J, Yatim N, Barnabel L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718\u201324.","journal-title":"Science"},{"key":"9188_CR101","unstructured":"Dasgupta, A. Seeking an Early COVID-19 drug, researchers look to interferons. The Scientist Magazine, 2020"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09188-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T18:40:36Z","timestamp":1724784036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09188-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["9188"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09188-2","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"<i>Army<\/i>: Views expressed in this paper are those of the author and do not purport to reflect official policy of the US Government or USAMRIID\/ARL administrators.Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the US Army.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}